Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764017130 Dexilant 30mg 30ct 01/03/2019 8.22 282.46 03/05/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764017530 Dexilant 60mg 30ct 01/03/2019 8.22 282.46 03/05/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764017590 Dexilant 60mg 90ct 01/03/2019 24.68 847.39 03/05/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764030020 Entyvio 300mg 20mL Vial 01/04/2019 182.92 6280.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 09/30/2019 64764030020 Entyvio 300mg 20mL Vial 07/03/2019 188.41 6468.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired from another company. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764080510 Rozerem 8mg 100ct 01/03/2019 37.76 1296.74 11/16/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764080530 Rozerem 8mg 30ct 01/03/2019 11.33 389.03 11/16/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764073030 Trintellix 10mg 30ct 01/03/2019 5.67 383.67 03/21/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764075030 Trintellix 20mg 30ct 01/03/2019 5.67 383.67 03/21/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764072030 Trintellix 5mg 30ct 01/03/2019 5.67 383.67 03/21/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764091830 Uloric 40mg 30ct 01/03/2019 9.63 330.03 09/08/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2019 64764067730 Uloric 80mg 30ct 01/03/2019 9.63 330.03 09/08/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459051230 ACTIQ 1200MCG 01/01/2019 422.10 4913.00 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459051630 ACTIQ 1600MCG 01/01/2019 520.80 6060.80 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459050230 ACTIQ 200MCG 01/01/2019 176.90 2058.60 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459050430 ACTIQ 400MCG 01/01/2019 223.90 2605.50 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459050630 ACTIQ 600MCG 01/01/2019 274.40 3193.20 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459050830 ACTIQ 800MCG 01/01/2019 324.80 3779.70 09/05/2006 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844011001 ADDERALL 10MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844011201 ADDERALL 12.5MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844011501 ADDERALL 15MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844012001 ADDERALL 20MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844013001 ADDERALL 30MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844010501 ADDERALL 5MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844011701 ADDERALL 7.5MG 100 01/01/2019 60.50 703.60 01/06/2021 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459070060 AMRIX 15 MG 01/01/2019 204.80 2383.00 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459070160 AMRIX 30 MG 01/01/2019 204.80 2383.00 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285052302 ANTABUSE 250MG 100 01/01/2019 70.80 824.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285052402 ANTABUSE 500MG 100 01/01/2019 113.30 1318.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285042410 AYGESTIN 5MG 50 01/01/2019 20.50 238.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 68546014256 AZILECT 0.5MG 30 01/01/2019 67.20 782.50 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 68546022956 AZILECT 1MG 30 01/01/2019 67.20 782.50 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 06/30/2019 00591280560 CLARITHROMYCIN 500MG ER TABLETS 60 04/10/2019 204.35 429.64 None Non-innovator Multiple Source Drug None 1 None 1 None 1 08/02/2016 Watson/Actavis None None Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price. 225.29 225.29 2014 225.29 None Teva temporarily discontinued this product on July 23, 2018, and reintroduced it on April 10, 2019.
Rx0000019 Teva Pharmaceuticals USA 06/30/2019 00703505103 DESMOPRESSIN ACETATE INJ 4MCG/ML 10X1ML 06/06/2019 536.20 595.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None This product was not acquired within the past 5 years. Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution.
Rx0000019 Teva Pharmaceuticals USA 06/30/2019 00703505401 DESMOPRESSIN ACETATE INJ 4MCG/ML 1X10ML 06/06/2019 536.20 595.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None This product was not acquired within the past 5 years. Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution.
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459054128 FENTORA 100MCG 01/01/2019 129.50 1506.90 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459054228 FENTORA 200MCG 01/01/2019 163.60 1903.90 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459054428 FENTORA 400MCG 01/01/2019 237.40 2762.40 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459054628 FENTORA 600MCG 01/01/2019 308.20 3586.40 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459054828 FENTORA 800MCG 01/01/2019 379.65 4418.30 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 52544008001 FIORICET 50/300/40MG 100 01/01/2019 44.00 512.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 08/02/2016 Watson/Actavis None 1 "Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." 449.93 None 2013 227.00 None "No patent expiration date listed - no patents ever listed"
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 52544008201 FIORICET/CODEINE 50/300/40/30MG 100 01/01/2019 92.10 1071.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 08/02/2016 Watson/Actavis None 1 "Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." 942.09 None 2013 475.00 None "No patent expiration date listed - no patents ever listed"
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459041230 GABITRIL 12MG 01/01/2019 31.20 362.70 06/10/2017 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459041630 GABITRIL 16MG 01/01/2019 40.80 474.90 06/10/2017 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459040230 GABITRIL 2MG 01/01/2019 24.10 280.50 06/10/2017 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459040430 GABITRIL 4MG 01/01/2019 24.10 280.50 06/10/2017 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844021552 GALZIN 25MG 250 01/01/2019 35.00 407.30 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 57844020852 GALZIN 50MG 250 01/01/2019 58.30 678.80 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285013197 LOESTRIN 21 1.0MG/20MCG 105 01/01/2019 56.80 661.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285012797 LOESTRIN 21 1.5MG/30MCG 105 01/01/2019 56.80 661.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285012870 LOESTRIN FE 28 1.5MG/30MCG 140 01/01/2019 56.80 661.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285012570 LOESTRIN FE 28 1MG/20MCG 140 01/01/2019 56.80 661.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285009287 LOSEASONIQUE 182 01/01/2019 66.10 769.00 12/05/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285012058 MIRCETTE 28 .15MG/.02MG .01MG 01/01/2019 71.20 828.50 10/20/2008 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459021530 NUVIGIL 150MG 01/01/2019 68.40 795.90 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459022030 NUVIGIL 200MG 01/01/2019 68.40 795.90 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Teva developed and launched the drug."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459022530 NUVIGIL 250MG 01/01/2019 68.40 795.90 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459020530 NUVIGIL 50MG 01/01/2019 22.70 264.50 06/18/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285006390 PREFEST 180 01/01/2019 72.50 844.00 03/20/2020 Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 59310057922 PROAIR INH AERO 90MCG 1INH 200 01/01/2019 5.36 64.93 05/18/2031 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.”
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 59310058020 PROAIR RESPICLICK 200 DOSE-117 01/01/2019 4.50 60.70 08/28/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.”
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 00575620030 PROGLYCEM 50MG/ML 30ML 01/01/2019 27.80 323.70 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed; CMS Market Date is defaulted to 1990."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459010130 PROVIGIL 100MG 01/01/2019 95.70 1113.70 05/29/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 63459020130 PROVIGIL 200MG 01/01/2019 144.60 1682.80 05/29/2024 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 59310020606 QNASL AERO 4.9GM 60 01/01/2019 18.87 228.55 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 59310021012 QNASL AERO 80MCG 8.7GM 120 01/01/2019 18.87 228.55 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285043187 QUARTETTE 182 01/01/2019 79.10 920.90 03/11/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285008787 SEASONIQUE 182 01/01/2019 66.10 769.00 12/05/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285055402 SURMONTIL 100MG 100 01/01/2019 101.90 1185.70 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285053802 SURMONTIL 25MG 100 01/01/2019 44.20 514.30 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285053902 SURMONTIL 50MG 100 01/01/2019 72.30 841.30 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285036801 TREXALL 10MG 01/01/2019 78.00 908.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285036901 TREXALL 15MG 01/01/2019 117.00 1362.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285036601 TREXALL 5MG 01/01/2019 39.00 454.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285036701 TREXALL 7.5MG 01/01/2019 58.50 681.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285004001 ZIAC 10MG/6.25MG 30 01/01/2019 16.70 194.00 03/24/2000 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285004702 ZIAC 2.5MG/6.25MG 100 01/01/2019 55.55 646.40 03/24/2000 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000019 Teva Pharmaceuticals USA 03/31/2019 51285005002 ZIAC 5MG/6.25MG 100 01/01/2019 55.55 646.40 03/24/2000 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None "The drug was not acquired within the last 5 years."
Rx0000134 Therakos, Inc. 03/31/2019 64067021601 UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML 01/01/2019 29.00 470.00 07/30/2008 Single Source Drug None 1 Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. None The current price increase for Uvadex is not necessitated by a change or improvement. Please see the Cost Increase Factors field for the larger principles set forth in our pledge. None 09/28/2015 The Gores Group None 1 None 360.00 300.00 2008 95.00 None None
Rx0000057 Theratechnologies Inc. 06/30/2019 62064001160 Tesamorelin Acetate 1 MG Solution Reconstituted 1 EA UD 04/08/2019 425.00 5300.00 05/26/2020 Single Source Drug None 1 None 1 Recent research has demonstrated a decrease in liver fat, which is an important health concern for patients living with HIV and lipohypertrophy On-going studies to assess the impact of Egrifta on people living with HIV and mild cognitive impairment None None None None None None None None None None None This product was developed by Theratechnologies Inc.